🚀 VC round data is live in beta, check it out!
Arcoma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Arcoma and similar public comparables like Lifecare, Scandinavian Medical, Scandinavian Real Heart, Trinity Biotech and more.
Arcoma Overview
About Arcoma
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
Founded
1990
HQ
Employees
31
Website
Sectors
Financials (LTM)
EV
$11M
Arcoma Financials
Arcoma reported last 12-month revenue of $15M and EBITDA of $2M.
In the same LTM period, Arcoma generated $6M in gross profit, $2M in EBITDA, and $768K in net income.
Revenue (LTM)
Arcoma P&L
In the most recent fiscal year, Arcoma reported revenue of $15M and EBITDA of $2M.
Arcoma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15M | XXX | $15M | XXX | XXX | XXX |
| Gross Profit | $6M | XXX | $6M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 39% | XXX | XXX | XXX |
| EBITDA | $2M | XXX | $2M | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $768K | XXX | $675K | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Arcoma Stock Performance
Arcoma has current market cap of $13M, and enterprise value of $11M.
Market Cap Evolution
Arcoma's stock price is $0.92.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11M | $13M | 0.3% | XXX | XXX | XXX | $0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArcoma Valuation Multiples
Arcoma trades at 0.7x EV/Revenue multiple, and 6.2x EV/EBITDA.
EV / Revenue (LTM)
Arcoma Financial Valuation Multiples
As of April 19, 2026, Arcoma has market cap of $13M and EV of $11M.
Equity research analysts estimate Arcoma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arcoma has a P/E ratio of 17.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13M | XXX | $13M | XXX | XXX | XXX |
| EV (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 6.2x | XXX | 6.7x | XXX | XXX | XXX |
| EV/EBIT | 12.6x | XXX | 15.5x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | 1.8x | XXX | XXX | XXX |
| P/E | 17.1x | XXX | 19.5x | XXX | XXX | XXX |
| EV/FCF | 9.8x | XXX | 7.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Arcoma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Arcoma Margins & Growth Rates
Arcoma's revenue in the last 12 month grew by 3%.
Arcoma's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Arcoma's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arcoma's rule of X is 26% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Arcoma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 25% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Arcoma Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Arcoma | XXX | XXX | XXX | XXX | XXX | XXX |
| Lifecare | XXX | XXX | XXX | XXX | XXX | XXX |
| Scandinavian Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Scandinavian Real Heart | XXX | XXX | XXX | XXX | XXX | XXX |
| Trinity Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Jana Medical Company | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arcoma M&A Activity
Arcoma acquired XXX companies to date.
Last acquisition by Arcoma was on XXXXXXXX, XXXXX. Arcoma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Arcoma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArcoma Investment Activity
Arcoma invested in XXX companies to date.
Arcoma made its latest investment on XXXXXXXX, XXXXX. Arcoma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Arcoma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Arcoma
| When was Arcoma founded? | Arcoma was founded in 1990. |
| Where is Arcoma headquartered? | Arcoma is headquartered in Sweden. |
| How many employees does Arcoma have? | As of today, Arcoma has over 31 employees. |
| Is Arcoma publicly listed? | Yes, Arcoma is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Arcoma? | Arcoma trades under ARCOMA ticker. |
| When did Arcoma go public? | Arcoma went public in 2014. |
| Who are competitors of Arcoma? | Arcoma main competitors are Lifecare, Scandinavian Medical, Scandinavian Real Heart, Trinity Biotech. |
| What is the current market cap of Arcoma? | Arcoma's current market cap is $13M. |
| What is the current revenue of Arcoma? | Arcoma's last 12 months revenue is $15M. |
| What is the current revenue growth of Arcoma? | Arcoma revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Arcoma? | Current revenue multiple of Arcoma is 0.7x. |
| Is Arcoma profitable? | Yes, Arcoma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Arcoma? | Arcoma's last 12 months EBITDA is $2M. |
| What is Arcoma's EBITDA margin? | Arcoma's last 12 months EBITDA margin is 11%. |
| What is the current EV/EBITDA multiple of Arcoma? | Current EBITDA multiple of Arcoma is 6.2x. |
| What is the current FCF of Arcoma? | Arcoma's last 12 months FCF is $1M. |
| What is Arcoma's FCF margin? | Arcoma's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Arcoma? | Current FCF multiple of Arcoma is 9.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.